Paladin Labs Inc. To Assume Pennsaid'R' Promotion

MONTREAL, CANADA -- (MARKET WIRE) -- December 01, 2006 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced that it will assume Canadian Pennsaid® (topical diclofenac) sales and marketing responsibilities from Solvay Pharma Inc. effective December 1, 2006. Paladin acquired the Canadian rights to Pennsaid® from Nuvo Research Inc. which included a co-promotional agreement with Solvay Pharma Inc.

Back to news